Opin vísindi

Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System

Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System


Title: Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System
Author: Vo, Christopher
Zomorodi, Rustin
Silvera, Richard
Bartram, Logan
Lugo, Luz Amarilis
Kojic, Erna
Urbina, Antonio
Aberg, Judith
Sigel, Keith
Chasan, Rachel
... 1 more authors Show all authors
Date: 2023-11
Language: English
Scope: 542014
University/Institute: Landspitali - The National University Hospital of Iceland
Series: Open Forum Infectious Diseases; 10(11)
ISSN: 2328-8957
DOI: 10.1093/ofid/ofad552
Subject: Smitsjúkdómalæknisfræði
URI: https://hdl.handle.net/20.500.11815/4680

Show full item record

Citation:

Vo , C , Zomorodi , R , Silvera , R , Bartram , L , Lugo , L A , Kojic , E , Urbina , A , Aberg , J , Sigel , K , Chasan , R & Patel , G 2023 , ' Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System ' , Open Forum Infectious Diseases , vol. 10 , no. 11 , pp. ofad552 . https://doi.org/10.1093/ofid/ofad552

Abstract:

BACKGROUND: The 2022 global mpox outbreak was notable for transmission between persons outside of travel and zoonotic exposures and primarily through intimate contact. An understanding of the presentation of mpox in people with human immunodeficiency virus (HIV) and other immunocompromising conditions and knowledge of the efficacy of tecovirimat continue to evolve. METHODS: This retrospective study describes clinical features and outcomes of persons with mpox who received tecovirimat. Data were obtained via medical record review of patients prescribed tecovirimat in a health system in New York City during the height of the outbreak in 2022. RESULTS: One hundred thirty people received tecovirimat between 1 July and 1 October 2022. People with HIV (n = 80) experienced similar rates of recovery, bacterial superinfections, and hospitalization compared to patients without immunocompromising conditions. Individuals determined to be severely immunocompromised (n = 14) had a higher risk of hospitalization than those without severe immunocompromise (cohort inclusive of those with well-controlled HIV, excluding those without virologic suppression, n = 101): 50% versus 9% (P < .001). Hospitalized patients (n = 18 [13% of total]) were primarily admitted for bacterial superinfections (44.4%), with a median hospital stay of 4 days. Of those who completed follow-up (n = 85 [66%]), 97% had recovery of lesions at time of posttreatment assessment. Tecovirimat was well tolerated; there were no reported severe adverse events attributed to therapy. CONCLUSIONS: There were no significant differences in outcomes between people with HIV when evaluated as a whole and patients without immunocompromising conditions. However, mpox infection was associated with higher rates of hospitalization in those with severe immunocompromise, including patients with HIV/AIDS. Treatment with tecovirimat was well tolerated.Key Points: In our mpox cohort, people with HIV had similar rates of recovery and complications as those without HIV or other immunocompromising conditions. Severe immunocompromise was associated with a higher hospitalization rate. Tecovirimat was well tolerated, with minimal side effects.

Description:

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Files in this item

This item appears in the following Collection(s)